Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
// Nicolas Pécuchet 1,2 , Pierre Laurent-Puig 1,3 , Audrey Mansuet-Lupo 4,5 , Antoine Legras 1 , Marco Alifano 6 , Karine Pallier 1 , Audrey Didelot 1 , Laure Gibault 7 , Claire Danel 8 , Pierre-Alexandre Just 4 , Marc Riquet 9 , Françoise Le Pimpec-Barthes 9 , Diane Damotte 4,5,* , Elisabeth Fabre 1,2,* and Hélène Blons 1,3,* 1 INSERM UMR-S1147, Paris Sorbonne Cité Université, Paris, France 2 Department of Medical Oncology, Hôpital Européen Georges Pompidou (HEGP), Assistance Publique, Hôpitaux de Paris, Paris, France 3 Department of Biochemistry, Pharmacogenetic and Molecular Oncology Unit, Hôpital Européen Georges Pompidou (HEGP), Assistance Publique, Hôpitaux de Paris, Paris, France 4 Department of Pathology, Hôpital Cochin, Assistance Publique, Hôpitaux de Paris, Paris, France 5 INSERM U1138, Paris Sorbonne Cité Université, Paris, France 6 Department of Thoracic Surgery, Hôpital Cochin, Assistance publique Hôpitaux de Paris, Paris, France 7 Department of Pathology, Hôpital Européen Georges Pompidou (HEGP), Assistance Publique, Hôpitaux de Paris, Paris, France 8 Department of Pathology, Hôpital Bichat, Assistance Publique, Hôpitaux de Paris, Paris, France 9 Department of Thoracic Surgery, Hôpital Européen Georges Pompidou (HEGP), Assistance Publique, Hôpitaux de Paris, Paris, France * These authors share senior authorship for this manuscript Correspondence: Hélène Blons, email: // Keywords : lung cancer, STK11, LKB1, isoforms, prognosis Received : July 20, 2015 Accepted : October 09, 2015 Published : November 25, 2015 Abstract STK11 is commonly mutated in lung cancer. In light of recent experimental data showing that specific STK11 mutants could acquire oncogenic activities due to the synthesis of a short STK11 isoform, we investigated whether this new classification of STK11 mutants could help refine its role as a prognostic marker. We conducted a retrospective high-throughput genotyping study in 567 resected non-squamous non-small-cell lung cancer (NSCLC) patients. STK11 exons 1 or 2 mutations (STK11 ex1-2 ) with potential oncogenic activity were analyzed separately from exons 3 to 9 (STK11 ex3-9 ). STK11 ex1-2 and STK11 ex3-9 mutations occurred in 5% and 14% of NSCLC . STK11 mutated patients were younger ( P = .01 ) and smokers ( P< .0001 ) . STK11 mutations were significantly associated with KRAS and inversely with EGFR mutations. After a median follow-up of 7.2 years (95%CI 6.8-.4), patients with STK11 ex1-2 mutation had a median OS of 24 months (95%CI 15-57) as compared to 69 months (95%CI 56-93) for wild-type (log-rank, P = .005 ) and to 91 months (95%CI 57-unreached) for STK11 ex3-9 mutations ( P = .003 ). In multivariate analysis, STK11 ex1-2 mutations remained associated with a poor prognosis ( P = .002 ). Results were validated in two public datasets. Western blots showed that STK11 ex1-2 mutatedtumors expressed short STK11 isoforms. Finally using mRNAseq data from the TCGA cohort, we showed that a stroma-derived poor prognosis signature was enriched in STK11 ex1-2 mutated tumors. All together our results show that STK11 ex1-2 mutations delineate an aggressive subtype of lung cancer for which a targeted treatment through STK11 inhibition might offer new opportunities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.029 · Cited by 1,789 · cited 12×
“Blons H, Pallier K, Le Corre D, Danel C, TremblayGravel M, Houdayer C, Fabre-Guillevin E, Riquet M, Dessen P, Laurent-Puig P. Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma.”
InfluentialLKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR‐1
Lizcano, J. M., Göransson, O., Toth, R., Deak, M., Morrice, N. A., Boudeau, J., Hawley, S. A., Udd, L., Mäkelä, T. P., Hardie, D. G., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600110 · Cited by 1,381 · cited 1×
“STK11 (LKB1) codes a serine/threonine kinase involved in the regulation of cell growth, polarity and motility [1].”
LKB1 modulates lung cancer differentiation and metastasis
Ji, H., Ramsey, M. R., Hayes, D. N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M. C., Shimamura, T., Perera, S. A., et al. (2007) · Nature · doi:10.1038/nature06030 · Cited by 1,064
Skoulidis, F., Byers, L. A., Diao, L., Papadimitrakopoulou, V. A., Tong, P., Izzo, J., Behrens, C., Kadara, H., Parra, E. R., Canales, J. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1236 · Cited by 936 · cited 2×
“Five-year overall survival was 53% [49-58] in the entire population, 29% [14-51], 53% [49-59] and 60% [48-71] in STK11ex1-2 mutation, wild-type STK11, and STK11ex3-9 mutation, respectively.”
Shackelford, D. B., Abt, E., Gerken, L., Vasquez, D. S., Seki, A., Leblanc, M., Wei, L., Fishbein, M. C., Czernin, J., Mischel, P. S., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.12.008 · Cited by 585 · cited 2×
“Five-year overall survival was 53% [49-58] in the entire population, 29% [14-51], 53% [49-59] and 60% [48-71] in STK11ex1-2 mutation, wild-type STK11, and STK11ex3-9 mutation, respectively.”
Wang, G. M., Wong, H. Y., Konishi, H., Blair, B. G., Abukhdeir, A. M., Gustin, J. P., Rosen, D. M., Denmeade, S. R., Rasheed, Z., Matsui, W., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1578 · Cited by 39 · cited 2×
“Five-year overall survival was 53% [49-58] in the entire population, 29% [14-51], 53% [49-59] and 60% [48-71] in STK11ex1-2 mutation, wild-type STK11, and STK11ex3-9 mutation, respectively.”
Cited by
Biton, J., Mansuet-Lupo, A., Pécuchet, N., Alifano, M., Ouakrim, H., Arrondeau, J., Boudou-Rouquette, P., Goldwasser, F., Leroy, K., Goc, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0163 · Cited by 351
Self-citationBiomarker Discovery and Validation: Statistical Considerations
Ou, F.-S., Michiels, S., Shyr, Y., Adjei, A. A., & Oberg, A. L. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.01.1616 · Cited by 258
Luo, P., Ding, Y., Lei, X., & Wu, F.-X. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00013 · Cited by 107
Bange, E., Marmarelis, M. E., Hwang, W.-T., Yang, Y.-X., Thompson, J. C., Rosenbaum, J., Bauml, J. M., Ciunci, C., Alley, E. W., Cohen, R. B., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00326 · Cited by 74
Bonanno, L., De Paoli, A., Zulato, E., Esposito, G., Calabrese, F., Favaretto, A., Santo, A., Conte, A. D., Chilosi, M., Oniga, F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2410 · Cited by 53
Metadata
- Authors
- Pécuchet, N., Laurent-Puig, P., Mansuet-Lupo, A., Legras, A., Alifano, M., Pallier, K., Didelot, A., Gibault, L., Danel, C., Just, P.-A., Riquet, M., Le Pimpec-Barthes, F., Damotte, D., Fabre, E., & Blons, H.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-11-25
- Volume
- 8
- Issue
- 14
- Pages
- 23831-23840
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2188278098
- Cited by
- 87
- References
- 7
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer. https://app.cochat.ai/papers/10.18632/oncotarget.6379
- The paper
- Pécuchet, N., Laurent-Puig, P., Mansuet-Lupo, A., Legras, A., Alifano, M., Pallier, K., Didelot, A., Gibault, L., Danel, C., Just, P.-A., Riquet, M., Le Pimpec-Barthes, F., Damotte, D., Fabre, E., & Blons, H. (2017). Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer. Oncotarget. https://doi.org/10.18632/oncotarget.6379
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.